UroGen licenses medac's mitomycin formulation for RTGel combo; plans Phase 3 for UGN-103

On January 16, 2024, UroGen Pharma Ltd. (the “Company”) entered into a license and supply agreement (the “Agreement”) with Medac Gesellschaft für klinische Spezialpräparate m.b.H. (“medac”), pursuant to which medac granted to the Company an exclusive, worldwide, royalty-free, sublicensable license under medac’s intellectual property rights to develop, commercialize, import, export, use, distribute and register the pharmaceutical lyophilized product—a specific 80 mg formulation of mitomycin and 640 mg urea, manufactured according to medac’s proprietary lyophilization process (the “Product”)—as an integrated part of a pharmaceutical product that includes the Product and a reverse thermal gel, including the Company’s RTGel® reverse thermal hydrogels (the “Combined Product”).